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Background: Animal models of human inflammatory diseases have limited predictive quality for human clinical
trials for various reasons including species specific activation mechanisms and the immunological background of
the animals which markedly differs from the genetically heterogeneous and often aged patient population.
Objective: Development of an animal model allowing for testing therapeutics targeting pathways involved in the
development of Atopic Dermatitis (AD) with better translatability to the patient.
Methods: NOD-scid IL2R γnull mice engrafted with human peripheral blood mononuclear cells (hPBMC) derived
from patients suffering from AD and healthy volunteers were treated with IL-4 and the antagonistic IL-4 variant
R121/Y124D (Pitrakinra). Levels of human (h)IgE, amount of B-, T- and plasma- cells and ratio of CD4 : CD8 positive
cells served as read out for induction and inhibition of cell proliferation and hIgE secretion. Results were compared
to in vitro analysis.
Results: hIgE secretion was induced by IL-4 and inhibited by the IL-4 antagonist Pitrakinra in vivo when formulated
with methylcellulose. B-cells proliferated in response to IL-4 in vivo; the effect was abrogated by Pitrakinra. IL-4
shifted CD4 : CD8 ratios in vitro and in vivo when hPBMC derived from healthy volunteers were used. Pitrakinra
reversed the effect. Human PBMC derived from patients with AD remained inert and engrafted mice reflected the
individual responses observed in vitro.
Conclusion: NOD-scid IL2R γnull mice engrafted with human PBMC reflect the immunological history of the donors
and provide a complementary tool to in vitro studies. Thus, studies in this model might provide data with better
translatability from bench to bedside.Introduction
A large number of drug candidates fail in clinical trials
due to lack of efficacy and unforeseen toxicity. This is
especially relevant in immunological diseases where ani-
mal models might not accurately reflect activation
mechanisms exerted in humans. The poor predictive
quality and translatability of present animal models has
been demonstrated in the clinical phase I study of TGN* Correspondence: roswitha.gropp@med.uni-muenchen.de
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distribution, and reproduction in any medium1412 [1] which tragically triggered a cytokine storm in
healthy volunteers despite being well tolerated in cyno-
molgus monkeys. The shortcomings of present animal
models also applies to chronic inflammatory diseases
since they mostly rely on the development of the disease
in 12-week-old inbred mice maintained under specific
pathogen free (SPF) conditions which markedly differ
from the pathophysiological mechanisms in the genetic-
ally heterogeneous and often aged patient populations
[2-4]. Last but not least mouse models cannot be used
when protein structures are not sufficiently conserved in
mice and humans.d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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are widely used for drug screening [5-8], but the example
of TGN 1412 has demonstrated that experimental condi-
tions might lead to difficulties in interpretation and trans-
latability of data [9]. Immunological reactions are very
often modulated and fine-tuned by temporary, spatial and
cell-specific expression of the respective cytokines and their
cognate receptors [10,11] and in vitro culture conditions
may inadequately reflect cell–cell interactions in lymphoid
organs in response to an immunological trigger [9].
Therefore, immune-compromised NOD-scid IL2R γnull
mice engrafted with human PBMC have become alterna-
tive models to study chronic inflammatory diseases such
as rheumatoid arthritis [12,13], AD and ulcerative colitis
(UC) [14,15]. It has been shown in the AD model, that the
immunological background of the donor is crucial
to the induction of atopic dermatitis like features and that
the immunological imprinting is preserved in vivo [14].
AD is a T-helper cell type 2 (Th2) driven inflammation
with interleukin-4 (IL-4) and interleukin 13 (IL-13) play-
ing key roles in the early edematous phase [16-18]. IL-4
activates the type I receptor complex consisting of the
IL-4 receptor α (IL-4Rα) and the so called common
gamma (γc) chain which is thought to be responsible for
proliferation and differentiation of T-cells. Both interleu-
kins, IL-4 and IL-13, can also activate the type II
interleukin-4 receptor complex consisting of IL-4Rα and
the IL-13 receptor α1 (IL-13α1) chain resulting in the
generation of phenotypic symptoms such as the im-
munoglobulin class switch from IgM to IgG4 and IgE, fi-
brosis, epithelial hyperplasia and barrier dysfunction
[19-21]. Therefore, both IL-4 receptor complexes have
been identified as therapeutic targets. One promising
approach is the development of the antagonistic IL-4
variant R121D/Y124D (Pitrakinra), which inhibits the
formation and activation of the IL-4 type I and II recep-
tor complexes and has already been tested successfully
in clinical phase II studies in asthma [22]. However, lim-
ited half-lives of IL-4 or mutant proteins are still a major
hurdle in their therapeutic use which results in the need
for daily applications of high doses [22-24].
Here we show that studies in NOD-scid IL2R γnull
mice engrafted with PBMC complement in vitro studies
with cultured hPBMC. IL-4 induced the secretion of IgE
in vitro and in vivo and Pitrakinra abolished the effect
of IL-4 as expected. In contrast to previous studies, for-
mulation with methylcellulose was instrumental to the
activating and inhibitory effect of IL-4 and Pitrakinra, re-
spectively. The proliferation-inducing effect was not
reflected in the spleen of engrafted mice; however, differ-
entiation of T-cells was similar in vitro and in vivo. Cell
batches which responded poorly in vitro were inert to
IL-4 treatment after transplantation into NOD-scid IL2R
γnull mice in vivo, indicating that the immunologicalcharacteristics of the human donors are preserved in the
animal hosts and that results of studies in this huma-
nized model might be better translatable to the patient.Material and methods
Production of wild-type IL-4 and Pitrakinra
Wildtype human IL-4 as well as the IL-4 antagonist/in-
hibitor Pitrakinra were produced in E. coli as described
[25]. The amino acid exchanges R121D/Y124D in IL-4
leading to the IL-4 inhibitor known as Pitrakinra were
introduced by a two-step PCR mutagenesis and correct-
ness of the cDNA was verified by didesoxy sequencing.
For protein production, the cDNA encoding for the ma-
ture part of human IL-4 or the variant R121D/Y124D was
cloned into the E. coli expression vector RBSIIPN25x/o
[26]. Transformed E. coli cells of the strain BL21 (DE3)
were grown in LB medium until an optical density of 0.6
to 0.8 at 600 nm was reached. Protein expression was
induced by addition of 1 mM IPTG (isopropyl-β-thioga-
lactosid), expression was continued for a further three
hours at 37°C. Cells were harvested by centrifugation and
lysed by ultrasonication. IL-4 as well as the variant Pitra-
kinra were expressed in insoluble form as inclusion bod-
ies, which were dissolved in 20 volumes (v/w) of 6 M
guanidinium hydrochloride (GuHCl), 50 mM Tris–HCl
pH 8.0. The denatured protein was refolded by a two-step
protocol, the first step comprising of a rapid five-fold dilu-
tion of the protein solution (protein concentration 2 mg/
ml) in 6 M GuHCl into ice-cold water. The solution was
stirred for 15 min and then dialyzed against 20 volumes
phosphate buffered saline (20 mM sodium phosphate,
120 mM NaCl, 2 mM KCl, pH 7.4) for 24 h at 4°C. The
protein solution was buffered to pH 5.5 using 4 M ammo-
nium actetate pH 4.5. Insoluble protein precipitate was
removed by centrifugation and the clear supernatant was
loaded onto a cation exchange column (GE Healthcare
CM sepharose FF). IL-4 was eluted by applying a linear
gradient of 0 to 1 M sodium chloride in 20 mM ammo-
nium acetate pH 5.5. IL-4 containing fractions were
pooled and subjected to a second purification employing a
reversed phase HPLC chromatography. Highly pure IL-4
protein was eluted using a linear gradient of 0.1% trifluor-
oacetic acid to 100% acetonitrile. Purity was checked by
SDS-PAGE and ESI-FT-ICR mass spectrometry. As a
quality control, the biological activities and receptor bind-
ing properties were examined by measuring the dose de-
pendency of TF-1 cell proliferation for wild-type human
IL-4 (EC50 of about 10 to 20 pM) as described, or for
Pitrakinra by dose-dependent inhibition of the TF-1 cell
proliferation [27]. Increasing concentrations of Pitrakinra
were added to TF-1 cells, which were simultaneously sti-
mulated with 100 pM wild-type IL-4, the half-maximal
concentration of inhibition of TF-1 cell proliferation IC50
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finity of the recombinant IL-4 proteins (wild-type and the
variant Pitrakinra) to its high-affinity receptor IL-4Rα was
determined by surface plasmon resonance was described
previously [28].
Isolation and engraftment of human PBMC
Peripheral blood was collected from patients suffering
from AD and healthy volunteers. Human PBMC were
purified by Ficoll-paque density gradient centrifugation.
30 ml of blood in sodium citrate solution was diluted
with 30 ml of HANKS Balanced Salt Solution (Sigma
Aldrich, Deisenhofen, Germany) and loaded on Leuco-
sep Tubes (Greiner Bio One, Frickenhausen, Germany).
Cells were separated at 800 × g for 15 min at RT
according to the manufacturer’s instruction. Human
PBMC were isolated, washed with HANKS Balanced
Salt Solution supplemented with 2500 IE Heparin So-
dium (Braun) and resuspended in phosphate buffered
saline (PBS) at a density of 20 × 106 / ml.
Six to 16 weeks old NOD-scid IL2Rγ null mice were
engrafted with 200 μl of the cell suspension (4 × 106 cells)
by intravenous injection. The average weight 24.5 ± 4 g.
Animals were randomized for age and sex. Following
engraftment the animals rested for 7 days.
Cell culture
4×106 hPBMC were resuspended in 2 ml RPMI, 10%
FCS (v/v), 1 mM sodium pyruvate, 10 U Penicillin/
Streptomycin, 2 mM Glutamine (Sigma, Deisenhofen,
Germany) and incubated for 14 days in a humidified
incubator at 37°C and 5% CO2 in 24 well plates supple-
mented with IL-4 (50 ng/ml) and 1 μl anti-CD 40
(1 μg/ml; BD Bioscience, Heidelberg, Germany) as pre-
viously described [29,30].
Study protocol
NOD.cg-Prkdcscid Il2rgtm1Wjl/Szj (abbreviated as NOD-
scid IL2R γnull) mice were obtained from Charles River
Laboratories (Sulzfeld, Germany). The mice were housed
under specific pathogen free (SPF) conditions in indi-
vidually ventilated cages. The facility is controlled
according to FELASA guidelines. Methylcellulose (A4C
Prem) was purchased from Fagron GmbH, Barsbüttel,
Germany).
Mice were engrafted on day one. Seven days post en-
graftment NOD-scid IL2Rγnull mice (6–16 weeks old)
were treated for five consecutive days (day 8–12) intra-
peritoneally with 10 μg IL-4 dissolved in PBS, or 10 μg
IL-4 dissolved in 0.5% methylcellulose (w/v), 0.05%
TWEEN 80 (v/v) in PBS or 10 μg IL-4 plus 100 μg Pitra-
kinra dissolved in 0.5% methylcellulose (w/v), 0.05%
(v/v) TWEEN 80 in PBS.
Mice were inspected daily and sacrificed at day 30.Serum hIgG and hIgE levels
Samples were blinded and human serum IgG levels
were measured turbidimetrically using COBAS INTE-
GRA 800 (Roche, Penzberg, Germany). Human serum
IgE levels were measured by the Elecsys 2010 Immuno-
assay (Roche, Penzberg, Germany). Murine IgE levels
were analyzed by Mouse IgE ELISA kit according to the
manufacturer’s instruction (BD Bioscience, Heidelberg,
Germany).Serum hIL-4 levels
Human serum IL-4 levels were measured using ELISA
IL-4 detection kit from BD Biosciences, Heidelberg,
Germany at day 10, 24 h post IL-4 administration.Flow cytometry analysis
Surface phenotyping of human lymphocytes
Labeling of the human lymphocytes, in human and
mouse, was performed using the following monoclonal
antibodies (mAbs): Anti-human CD3- FITC (clone
SK7), anti-human CD4-PE (clone SK3), anti-human
CD8-APC (clone SK1), anti-human CD19-APC (clone
SJ25C1), anti-human CD38-PE (clone HIT2), anti-
human CD45-APC-H7 (clone 2D1), anti-human CD56-
PerCP-CY™ 5.5 (clone B159), anti-human CD138-FITC
(clone MI15). Anti-mouse CD45 –PE-Cy™ 7 (clone30-
F11) staining was performed to exclude all murine host
cells from the analysis as well as to check for cross-
reactivity with human cells. All mAbs were purchased
from BD Biosciences, Heidelberg, Germany.
Human peripheral blood was taken from the vein in
heparinized tubes. At the time of sacrifice peripheral
mouse blood was collected in heparin coated tubes from
the anesthetized mouse by cardiocentesis. 100 μl of
blood was stained with appropriate antibodies and incu-
bated for 15 min at room temperature in darkness. The
erythrocytes were removed from the samples using 1×
BD FACS Lysing Solution (BD Biosciences, Heidelberg,
Germany) for 10 min at RT and darkness.
Single cell suspensions were prepared from the spleen
in RPMI-1640 containing 10% FCS by mincing with a
metal mesh followed by a 100 μm cell strainer (BD Bios-
ciences). The cells were treated by 1× BD Pharm lyse
(BD Biosciences, Heidelberg, Germany) for 10 min at
RT. Following the washing process in 2% RPMI-1640
(Sigma-Aldrich, Germany), 106 cells/ml were labeled with
appropriate antibodies.
Following staining the cells were washed in FACS buf-
fer (PBS containing 2% FCS) and resuspended in 500 μl
of the same.
At least 10.000 events were measured using FACS Canto
(BD Biosciences, Heidelberg, Germany). Post-acquisition
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Star, Ashland, OR).
Statistical analysis
Statistical analyses were performed using R a free software
environment for statistical computing and graphing (www.
r-project.org). Group means were compared with analysis
of variance (ANOVA), followed by Tukey’s test for mul-
tiple comparisons. Where assumptions for ANOVA were
not fulfilled, Kruskal Wallis test was applied.
Ethical considerations
All donors gave informed written consent and the study
was approved by the IRB of the Medical Faculty at the
University of Munich.
All animal studies were approved by the Ethics Com-
mittee for animal use of the government of Upper
Bavaria, Germany (55.2-1-54-2531-57-10) and performed
in compliance with German Animal Welfare Laws.
Results
Formulation of IL-4 with methylcellulose induces the
secretion of hIgE
In order to examine whether the formulation of IL-4 with
methylcellulose enhances the secretion of hIgE in NOD-
scid IL2R γnull mice engrafted with hPBMC, hIgE levels
were measured in animals treated with 10 μg IL-4 in PBS
(IL-4, n = 10) and animals treated with 10 μg IL-4 formu-
lated with 0.5% methylcellulose, 0.05% TWEEN 80 in PBS
(IL-4 +Methylcellulose, n = 12). Engrafted animals treated
with carrier alone (Methylcellulose, n = 4) served as con-
trol. As we knew from previous experiments [14,15], that
the responsiveness to IL-4 is dependent on the immuno-
logical background of the donors and their current
immunological status, all hPBMC were analyzed simultan-
eously in vitro with respect to their capacity to secrete IgE
in response to IL-4. Human PBMC were isolated as
described in material and methods and 4 × 106 cells were
incubated for 14 days with 50 ng/ml IL-4 as previously
described [29]. The induction of hIgE synthesis was mea-
sured in the supernatant by immuno assay and turbidi-
metric measurement. Human PBMC from two volunteers
without any symptoms of AD and thus considered as
‘healthy’ responded similarly to IL-4 in vitro. Human
PBMC from one donor (non-AD1) who had no history of
allergy displayed mean values of IgE of 200 ± 94 ng/ml
(n = 6) in vitro, whereas hPBMC from the other donor
(non-AD2) who experienced rare allergic reactions dis-
played mean IgE values of 275 ± 126 ng/ml (n = 4).
Human PBMC of these donors were repeatedly isolated
and engrafted into NOD-scid IL2R γnull mice; cohorts
consisted of four to six animals. In addition, two donors
suffering from AD (AD1, AD2) were included in the
study. The isolated hPBMC of both responded uponexposure to IL-4 in vitro with the secretion of hIgE (244
and 4248 ng/ml, respectively). Eight days post engraftment
mice were treated for five consecutive days as described
above according to the treatment regime defined by the
respective regime of the group. At day 30 all animals were
sacrificed and their blood was analyzed for hIgE levels. As
shown in Figure 1 we observed elevated levels only when
IL-4 was formulated with methylcellulose. In this group
the median level was 33.1 ng/ml as compared to 1.8 ng/
ml in the group treated with IL-4 dissolved in PBS and
0 ng/ml in control group treated with carrier alone. The
analysis of the data revealed that hIgE levels were signifi-
cantly different (Kruskal-Wallis, p = 0.013). In this experi-
ment, we observed no difference between the AD and
non-AD groups.
The formulation with methylcellulose prolongs the
presence of IL-4 in vivo
In order to examine whether the formulation with
methylcellulose results in a prolongation of the half- life
of IL-4 in vivo, hIL-4 levels were measured in mouse
sera as described in material and methods. Blood was
drawn at day 9, 24 h after hIL-4 administration in
engrafted animals treated with IL-4 dissolved in PBS
(n = 4), methylcellulose (n = 4) and IL-4 dissolved in
methylcellulose (n = 11). As shown in Figure 2 hIL-4
levels in mouse sera were below detection level in the
“IL-4” and “Methylcellulose“ groups and reached a me-
dian of 1.95 ng/ml in the “IL-4 +Methylcellulose” group
which was significantly different from the other groups.
(ANOVA, F = 4.3, p = 0.03).
The inhibitory effect of the IL-4 variant Pitrakinra on hIgE
secretion in vitro and in vivo
In order to examine whether this animal model might
be useful to study inhibitors addressing targets of human
inflammatory pathways we analyzed the effect of the IL-
4 variant R121D/Y124D (henceforward the variant will
be referred to as antagonist or Pitrakinra) in NOD-scid
IL2R γnull mice engrafted with hPBMC. To determine
the correct dosage of the IL-4 antagonist, hPBMC
derived from healthy volunteers and patients suffering
from AD were incubated in vitro with 50 ng/ml IL-4 in
the absence or presence of increasing concentrations of
the antagonist (50–500 ng/ml). As in previous experi-
ments hIgE levels were measured by turbidimetry at day
14 with high variability in hIgE levels being seen in both
groups upon exposure to IL-4. In order to normalize the
inhibitory capacity of the IL-4 antagonist, hIgE values
measured in the sample exposed to IL-4 were defined as
100% and the inhibitory effect of antagonist as % change in
comparison to the sample treated with IL-4 alone. As
shown in Figure 3A secretion of hIgE decreased with in-
creasing antagonist concentration, however, the susceptibility
Figure 1 IL-4 dependent hIgE secretion. Human PBMC were repeatedly isolated from two different donors and incubated in the absence
(control; n = 10) or presence of IL-4 (50 ng/ml; n = 10). After 14 days the hIgE level was determined in the supernatant. For in vivo stimulation of
hIgE secretion in NOD-scid IL2R γnull mice engrafted with hPBMC from the same donors the animals were treated on five consecutive days (8–12)
with 10 μg IL-4, dissolved in PBS (IL-4, n = 10) or 0.5% methylcellulose, 0.05% TWEEN 80 (IL-4 + Methylcellulose; n = 12). Administration of 0.5%
methylcellulose, 0.05% TWEEN 80, PBS (Methylcellulose, n = 4) served as control. IgE levels were significantly different in the three in vivo groups
(Kruskal Wallis test, p = 0.015).
Figure 2 Formulation dependent IL-4 plasma levels. Engrafted
NOD-scid IL2R γnull mice were treated with 10 μg hIL-4 dissolved in
PBS (IL-4; n = 4), 0.5% methylcellulose, 0.05% TWEEN 80 in PBS
(Methylcellulose; n = 4) and 10 μg IL-4 formulated with 0.5%
methylcellulose, 0.05% TWEEN 80 in PBS (IL-4 + Methylcellulose;
n = 11) for five consecutive days (day 8–12). IL-4 serum levels were
determined at day 10 24 h post administration. Human IL-4 mouse
serum levels in the group “IL-4 + Methylcellulose” were significantly
different from the other groups. (ANOVA , F = 4.3, p = 0.03).
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compared to the non-AD group. At a concentration of
100 ng / ml antagonist the median change in the AD group
was 33.6%, while in the non-AD group the median was
89% and this was statistically significant (Kruskal-Wallis
rank sum test, p = 0.02). When the antagonist concentra-
tion exceeded the IL-4 concentration by a factor of 10 the
remaining hIgE levels were close to zero in both groups.
Therefore, for in vivo studies animals were treated with
10 μg IL-4 in methylcellulose or 10 μg IL-4 plus 100 μg
Pitrakinra in methylcellulose. Otherwise, treatment regimes
were identical to those used in the previous experiments.
Animals were engrafted with hPBMC derived from four
donors suffering from AD and two without any history of
atopic dermatitis. Cohorts consisted of four to six animals.
As in the in vitro experiments the values were normalized.
Mean values of hIgE in the IL-4 treated cohorts were
defined as 100% and compared to mean values of the
cohorts treated with IL-4 and antagonist. As shown in
Figure 3B the median inhibition of hIgE secretion was
22%. The differences between both groups were not
statistically significant, but a strong trend was indicated
(p = 0.07; Kruskal- Wallis rank sum test).
FACS analysis of hPBMC and splenic human lymphocytes
In order to analyze to effect of Pitrakinra on T- and B-
cells in vivo and in vitro, hPBMC and isolated human
lymphocytes were subjected to FACS analysis. hPBMC
Figure 3 Antagonist concentration dependent inhibition of hIgE secretion. A, in vitro; Isolated hPBMC derived from patients suffering from
AD (n = 5) and from donors without any history of AD (Non-AD, n = 7) were incubated for 14 days in the presence of 50 ng/ml IL-4 and
increasing amounts of antagonist (1:1, 50 ng/ml; 1:2, 100 ng/ml; 1:5, 250 ng/ml; 1:10, 500 ng/ml). At a concentration ratio of 1:2 the difference in
the AD group was statistically different from the non-AD group (Kruskall-Wallis test, p = 0.02). B, in vivo; hPBMC derived from patients suffering
from AD (n = 4) and from one donor without any history of atopic dermatitis (n = 1) were engrafted and treated with 10 μg IL-4 in 0.5%
methylcellulose, 0.05% TWEEN 80 in PBS (1:0) or 10 μg + 100 μg antagonist in 0.5% methylcellulose, 0.05% TWEEN 80 in PBS (1:10). In every cohort
(n = 4-5) mean serum hIgE levels were determined. Mean hIgE levels of IL-4 treated animals were defined as 100%. Analysis of the data revealed
that the change was not statistically different.
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were incubated with 50 ng IL-4 or 50 ng IL-4 + 500 ng
antagonist as previously described. After 14 days the
total numbers of cells were counted in 100 μl of the cell
culture.
For the in vivo studies animals were engrafted and
treated as in the previous study. The AD group con-
sisted of three different donors and the non-AD group
consisted of two different donors. The groups were fur-
ther subdivided into the three different treatment
groups: “No treatment”, “IL-4” and “IL-4 + Antagonist”
(Table 1).
Cohorts consisted of three to six animals. At day 30
the animals were sacrificed and the splenic lymphocytesTable 1 Number of animals in the study
Diagnosis AD




No 4 3 3
IL-4 18 16 15
IL-4 + Antagonist 19 18 13
Total number 41 37 31were isolated as described in material and methods.
Engraftment levels were determined by counting of
human CD45 positive cells among splenic lymphocytes.
In both groups engraftment levels varied significantly
and ranged from 0.3 to 71%. There was a strong trend
that hPBMC from patients with AD did engraft at higher
levels (p = 0.06; Kruskal-Wallis rank sum test). The me-
dian engraftment level in the AD group was 16% as
compared to the median of 5.5% in the non-AD group.
Treatment regimen had no effect on engraftment levels.
Animals with engraftment levels below 1% were consid-
ered non-engrafted and excluded from the analysis. This
criterion applied to six animals of the AD group and 12
of the non-AD group (Table 1).Non-AD
Δ Engrafted At the end
of experiment
analyzed Δ
1 10 10 8 2
3 20 20 14 6
6 10 9 5 5
10 40 39 27 13
Zadeh-Khorasani et al. Journal of Translational Medicine 2013, 11:4 Page 7 of 10
http://www.translational-medicine.com/content/11/1/4The effect of Pitrakinra on B- and plasma-cells in vitro and
in vivo
As IL-4 is known to induce proliferation and differenti-
ation of B-cells we analyzed the impact of IL-4 and an-
tagonist in vitro and in vivo by FACS analysis of isolated
hPBMC and isolated human splenic lymphocytes from
the engrafted animals. For in vitro analysis, the number
of B-cells (CD19+) was determined in 100 μl of the cell
suspension by FACS analysis. For in vivo analysis,
splenic B-cells (CD19+) were isolated from the spleen as
described in material and methods and the percentage
of B-cells was determined by FACS analysis. As shown
in Figure 4, treatment with IL-4 resulted in a decline of
B-cells after 14 d incubation without any treatment and
IL-4 had only a minor effect on total B-cell numbers
in vitro. In contrast, IL-4 had a pronounced effect on
plasma -cells in vitro (CD19+ + CD138+). At day 1 (me-
dian = 3) almost no plasma-cells were detectable. The
cell culture conditions alone seemed to induce differen-
tiation of plasma-cells as shown by the increase of the
median at day 14 (median = 148), an effect which wasFigure 4 Effect of antagonist on B- and plasma-cells in vitro and in vi
or 50 ng IL-4 + 500 ng Pitrakinra for 14 days. The number of B-cells CD19+ an
suspensions. Statistical analysis revealed that the difference in Plasma-cells in
were engrafted with hPBMC and left without treatment (No, n = 9), treated w
methylcellulose (n = 12). The percentage of B- and plasma cells of human lym
in B-cells in the “IL-4” group was significant (Kruskal-Wallis rank sum test, p = 0enhanced by IL-4 (median = 201) and abrogated by antag-
onist (median = 87). Statistical analysis of log transformed
data revealed that the “IL-4” group was significantly differ-
ent from all the other groups (ANOVA, F = 6.3, p = 0.01).
These results differ from those obtained from the ana-
lysis of human lymphocytes recovered from mouse
spleens. Here, treatment with 10 μg IL-4 plus methylcel-
lulose resulted in an in increase of B-cells (median =
5.8%) as compared to the non-treated group (median =
1%) and treatment with 10 μg IL-4 plus 100 μg antagon-
ist reduced the percentage of B-cells (median = 0.82%).
Statistical analysis revealed that the “IL-4” group was
significantly different from the “IL-4 + Antagonist” group
(p = 0.05). In contrast, no effect on plasma cells was
observed in vivo.
The effect of Pitrakinra on T- cells in vitro and in vivo
In order to analyze the effect of IL-4 and Pitrakinra on
T-cells and subsets of T-cells, human T-cells from the
in vitro and in vivo experiments were subjected to FACS
analysis. As shown in Figure 5, IL-4 had a strongvo. In vitro: hPBMC (n = 8) were incubated in the presence of 50 ng IL-4
d plasma cells CD19+ + CD 138+ was determined in 100 μl of cell
the “IL-4” group was significant (ANOVA, F = 6.3, p = 0.01). In vivo: Mice
ith 10 μg IL-4 in methylcellulose (n = 18), and IL-4 + Antagonist in
phocytes was determined. Statistical analysis revealed that the difference
.03).
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fect was more pronounced in the non-AD group (n = 4),
where total numbers increased by a factor of 3.9 (me-
dian = 51078) as compared to a factor of 2.8 in the AD-
group (n = 7; median = 48040). The difference was not
statistically significant. IL-4 and Pitrakinra had no effect
on proliferation of T-cells in the spleen of the engrafted
mice (data not shown).
As IL-4 is known to influence the ratio of CD4+ : CD8+
T-cells we further analyzed the ratios in vitro and in vivo.
Although IL-4 induced the proliferation of both,
CD4+ and CD8+ cells (data not shown), the effect was moreNon-AD A
A
B
Figure 5 Impact of IL-4 and antagonist on T-cells in vitro and in vivo.
proliferation of T-cells and differentiation of CD4 cells in vitro (AD, n = 7; no
presence of 50 ng/ ml IL-4 (IL-4) or 50 ng IL-4 + 500 ng/ml antagonist (IL-4
response to IL-4 and antagonist in vitro and in vivo. Non-AD; No treatment
= 3; IL-4, n = 4, IL4 + Antagonist, n = 4) and AD2 (IL-4, n = 7; IL4 + Antagopronounced in CD4+ cells. Unexpectedly, this effect was
only observed in the non-AD group. As shown in Figure 5
the ratio in the AD group did not change significantly
and was not affected by the antagonist. Mean values
were 2.4 ± 0.8 at day 1, slightly increased during the in-
cubation period to 3.6 ± 1.95 at day 14 in the absence
of IL-4 and to 4.2 ± 1.16 in the presence of IL-4 and
remained at a level of 4.1 ± 0.75 in the presence of an-
tagonist. This was profoundly different in the non-AD
group where mean values increased from 2.2 ± 0.6 at
day 1 to 3.9 ± 7.2 at day 14 in the absence of IL-4 and
significantly increased by a factor of 1.8 to a level ofD1 AD2
A, Relevance of the immunological background on IL-4 induced
n-AD, n = 4). Isolated hPBMC were incubated in the absence (No) or
+ Antagonist). B, Comparison of individual CD4 : CD8 ratios in
(No), n = 6; IL-4, n = 11, IL4 + Antagonist, n = 5), AD1 (No treatment, n
nist, n = 5). Dotted lines indicate respective in vitro ratios at day 14.
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and caused a decrease to a level of 5 ± 2. Statistical ana-
lysis revealed that the “IL-4” group was statistically differ-
ent from all other groups (F = 6.5, p = 0.008 ANOVA
multiple comparison).
To test whether these responses were reflected in
engrafted animals, we compared the CD4+ : CD8+ ratios
in response to IL-4 and antagonist of individual donors
in vitro and in vivo. The analysis of CD4+ : CD8+ ratios
revealed that the pattern was preserved (Figure 5) whereby
the non-AD donor was markedly stimulated by IL-4
(No treatment, n = 6; IL-4, n = 11, IL-4 + Antagonist,
n = 5), AD1 moderately stimulated (No treatment, n = 3;
IL-4, n = 4, IL4 + Antagonist, n = 4) and AD2 not stimu-
lated (IL-4, n = 7; IL4 + Antagonist, n = 5) by IL-4 and an-
tagonist in vitro and in vivo.
Discussion
In this study we describe the development of an animal
model that closely reflects the immunological back-
ground of the individual human donor and allows for
the studying of inhibitors addressing human therapeutic
targets involved in chronic inflammatory diseases such
as AD in vivo. NOD-scid IL2R γnull mice were engrafted
with hPBMC derived from patients suffering from AD
and from healthy volunteers and treated with IL-4 or the
IL-4 antagonist/inhibitor Pitrakinra. We chose IL-4 and
its inhibitor Pitrakinra as a model system as the effects
of both have been thoroughly characterized in vitro and
both have been examined in clinical studies [22,24]. A
major problem with in vivo studies has been the short
half-life of IL-4 and Pitrakinra [31,32]. In contrast to
previous studies [30,32] we observed no effect when IL-
4 was dissolved in PBS which may reflect that in our
experiments approximately a tenth of the cell numbers
of hPBMC were used for engraftment or the use of dif-
ferent mouse strains. In our studies, hIgE secretion was
significantly induced when IL-4 was formulated with
methylcellulose, irrespective of the atopic background of
the donor. Finally, the IgE secretion reflected the
observed induction in vitro. The effect was most prob-
ably due to an inhibition of the rapid secretion of IL-4
by methylcellulose. In contrast to IL-4 administered with
PBS, IL-4 formulated with methylcellulose could be
detected in the sera of respective mice 24 h post admin-
istration in therapeutic concentrations. However, we
cannot conclude from these studies, that long time ex-
posure to IL-4 is also required for priming dendritic cells
or T-cells since Biedermann et al. [33] have shown that
short time exposure to IL-4 without formulation is suffi-
cient to prime dendritic cells in vivo.
Next we analyzed whether the inhibitory effect of
Pitrakinra on IgE secretion is reflected in this model.
Surprisingly hPBMC derived from AD patients andhealthy volunteers responded differently to Pitrakinra
in vitro. At lower concentration there seemed to be no ef-
fect on hIgE secretion in the AD group, while the non-AD
group responded to the IL-4 inhibitor. At a ratio of 1: 10
of IL-4 and antagonist both groups responded similarly
and the inhibition was also seen in the engrafted animals.
The effect of IL-4 and Pitrakinra on B- and plasma
cells produced mirror image results when in vitro and
in vivo experiments were compared, indicating that in
this case the environment of the spleen may influence
the action and effect of immune-modulatory agents. In
the spleen IL-4 induced the proliferation of B-cells and
Pitrakinra reversed this effect, while in vitro B-cell
numbers did not increase. Conversely, plasma cells
proliferated in vitro in response to IL-4 and Pitrakinra
whereas in the spleen no effect of IL-4 and Pitrakinra
was detected.
Opposing effects of IL-4 on T-cells were observed
in vitro and in vivo studies. As expected, IL-4 induced
significant proliferation of T-cells in vitro, an effect that
was significantly inhibited by Pitrakinra. In contrast,
treatment with IL-4 or Pitrakinra had no effect on
engraftment- or T-cell levels in in vivo studies.
As expected, IL-4 exerted its capacity to differentiate
T-cells in vitro and in vivo similarly. IL-4 tipped the bal-
ance of CD4+: CD8+ in favor of CD4+ cells an effect that
was abrogated by Pitrakinra. An interesting and unex-
pected observation in these experiments was the appar-
ent influence of the immunological background of the
donor on the response. PBMC from AD patients hardly
responded in in vitro studies and individual responses
seen in vitro were well reflected in vivo studies.
Recent studies have shown that high density cell cul-
ture of hPBMC mimics cell-cell interactions in lymphoid
organs [9]. In our experiments, exposure to IL-4 for
24 h did not prime the cells to produce IgE (data not
shown); instead long time incubation was required. The
observed individual responses to IL-4 and Pitrakinra in-
dicate that analysis of hPBMC may provide evidence for
potential responses in clinical trials. The analysis of the
same hPBMC in engrafted mice further allows for
detailed studies in lymphoid organs.
In summary, we present an animal model which has
the potential to provide data with higher translatability
to the patient as compared to conventional mouse mod-
els. It complements in vitro studies and can be used to
stratify patients for later clinical studies.
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